Ott H W, Mattle V, Hadziomerovic D, Licht P, Döinghaus K, Rubbert A, Manger K, Manger B, Kalden J, Wildt L
Clinical Division of Gynaecological Endocrinology and Reproductive Medicine, Medical University of Innsbruck, Austria.
Clin Endocrinol (Oxf). 2007 Feb;66(2):180-4. doi: 10.1111/j.1365-2265.2006.02704.x.
Eight women, aged 25-58 years, with hereditary angioneurotic oedema (HANE) were treated with tibolone, a synthetic steroid exhibiting oestrogenic, androgenic and progestational activity.
Pilot study.
Tibolone at a dose of 2.5-7.5 mg/day significantly reduced the number and severity of attacks and the number of ampoules of C1-esterase inhibitor (C1-INH) needed for symptomatic therapy. The efficacy of tibolone was comparable to that of danazol, while the androgenic side-effects were considerably reduced.
Tibolone may represent an alternative to danazol administration for the prophylaxis of HANE in women.
对8名年龄在25 - 58岁之间的患有遗传性血管性水肿（HANE）的女性，使用替勃龙进行治疗。替勃龙是一种具有雌激素、雄激素和孕激素活性的合成类固醇。
试点研究。
每日剂量为2.5 - 7.5毫克的替勃龙显著减少了发作的次数和严重程度，以及症状治疗所需的C1酯酶抑制剂（C1-INH）安瓿数量。替勃龙的疗效与达那唑相当，而雄激素副作用则大幅减少。
替勃龙可能是女性预防遗传性血管性水肿时替代达那唑给药的一种选择。
